Avsnittsbeskrivning
GLSI stock analysis: 0% recurrence sparks +685% upside — buy or sell valuation
👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends
In this deep dive, we break down Greenwich LifeSciences, Inc. (GLSI) and the pivotal Phase III FLAMINGO-01 clinical trial for its lead breast cancer immunotherapy candidate, GLSI-100. With shares trading near $15.28 against a probability-weighted valuation target of $120.03 alongside ongoing cash burn and binary trial…
Webbplats: flash.stocksentinel.ai

